Fosfomycin (English Wikipedia)

Patel SS, Balfour JA, Bryson HM (April 1997). "Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections". Drugs. 53 (4): 637–656. doi:10.2165/00003495-199753040-00007. PMID 9098664. S2CID 46972404.
Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI (April 2008). "Fosfomycin: use beyond urinary tract and gastrointestinal infections". Clinical Infectious Diseases. 46 (7): 1069–1077. doi:10.1086/527442. PMID 18444827.
Falagas ME, Grammatikos AP, Michalopoulos A (October 2008). "Potential of old-generation antibiotics to address current need for new antibiotics". Expert Review of Anti-Infective Therapy. 6 (5): 593–600. doi:10.1586/14787210.6.5.593. PMID 18847400. S2CID 13158593.
Zhanel GG, Zhanel MA, Karlowsky JA (28 March 2020). "Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections". The Canadian Journal of Infectious Diseases & Medical Microbiology. 2020 8513405. Hindawi Limited. doi:10.1155/2020/8513405. PMC 7142339. PMID 32300381.
Meschiari M, Faltoni M, Kaleci S, Tassoni G, Orlando G, Franceschini E, et al. (May 2024). "Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience". International Journal of Antimicrobial Agents. 63 (5) 107134. doi:10.1016/j.ijantimicag.2024.107134. hdl:11380/1334689. PMID 38453094.
Zerbato V, Sanson G, Fusaro L, Gerussi V, Sincovich S, Dellai F, et al. (14 April 2025). "Intravenous Fosfomycin for Difficult-to-Treat Infections: A Real-Life Multicentric Study in Italy". Antibiotics. 14 (4): 401. doi:10.3390/antibiotics14040401. ISSN 2079-6382. PMC 12024000. PMID 40298561.
Antonello RM, Principe L, Maraolo AE, Viaggi V, Pol R, Fabbiani M, et al. (August 2020). "Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies". Antibiotics. 9 (8): 500. doi:10.3390/antibiotics9080500. PMC 7460049. PMID 32785114.
Antonello RM, Di Bella S, Maraolo AE, Luzzati R (June 2021). "Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies". European Journal of Clinical Microbiology & Infectious Diseases. 40 (6): 1117–1126. doi:10.1007/s10096-021-04181-x. PMC 8139892. PMID 33604721.
Di Bella S, Mearelli F, Gatti M (February 2025). "The importance of antibiofilm antibiotics in hardware-associated infections". Clinical Infectious Diseases ciaf064. doi:10.1093/cid/ciaf064. PMID 39935305.
Navas J, León J, Arroyo M, García Lobo JM (October 1990). "Nucleotide sequence and intracellular location of the product of the fosfomycin resistance gene from transposon Tn2921". Antimicrobial Agents and Chemotherapy. 34 (10): 2016–2018. doi:10.1128/AAC.34.10.2016. PMC 171982. PMID 1963292.
Kahan FM, Kahan JS, Cassidy PJ, Kropp H (May 1974). "The mechanism of action of fosfomycin (phosphonomycin)". Annals of the New York Academy of Sciences. 235 (1): 364–386. Bibcode:1974NYASA.235..364K. doi:10.1111/j.1749-6632.1974.tb43277.x. PMID 4605290. S2CID 33013586.
Castañeda-García A, Blázquez J, Rodríguez-Rojas A (April 2013). "Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance". Antibiotics. 2 (2): 217–236. doi:10.3390/antibiotics2020217. PMC 4790336. PMID 27029300.
Omori K, Kitagawa H, Takada M, Maeda R, Nomura T, Kubo Y, et al. (April 2024). "Fosfomycin as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia: A case series and review of the literature". J Infect Chemother. 30 (4): 352–356. doi:10.1016/j.jiac.2023.10.024. PMID 37922987.
Lagatolla C, Mehat JW, La Ragione RM, Luzzati R, Di Bella S (September 2022). "In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium". Antibiotics. 11 (10): 1334. doi:10.3390/antibiotics11101334. PMC 9598191. PMID 36289992.
Rigsby RE, Fillgrove KL, Beihoffer LA, Armstrong RN (2005). "Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily". Gluthione [sic] Transferases and Gamma-Glutamyl Transpeptidases. Methods in Enzymology. Vol. 401. pp. 367–379. doi:10.1016/S0076-6879(05)01023-2. ISBN 978-0-12-182806-6. PMID 16399398.
Sharma SV, Jothivasan VK, Newton GL, Upton H, Wakabayashi JI, Kane MG, et al. (July 2011). "Chemical and Chemoenzymatic syntheses of bacillithiol: a unique low-molecular-weight thiol amongst low G + C Gram-positive bacteria". Angewandte Chemie. 50 (31): 7101–7104. doi:10.1002/anie.201100196. PMID 21751306.
Roberts AA, Sharma SV, Strankman AW, Duran SR, Rawat M, Hamilton CJ (April 2013). "Mechanistic studies of FosB: a divalent-metal-dependent bacillithiol-S-transferase that mediates fosfomycin resistance in Staphylococcus aureus". The Biochemical Journal. 451 (1): 69–79. doi:10.1042/BJ20121541. PMC 3960972. PMID 23256780.
García P, Arca P, Evaristo Suárez J (July 1995). "Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate". Antimicrobial Agents and Chemotherapy. 39 (7): 1569–1573. doi:10.1128/aac.39.7.1569. PMC 162783. PMID 7492106.
Brown ED, Vivas EI, Walsh CT, Kolter R (July 1995). "MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli". Journal of Bacteriology. 177 (14): 4194–4197. doi:10.1128/jb.177.14.4194-4197.1995. PMC 177162. PMID 7608103.
Zhu JY, Yang Y, Han H, Betzi S, Olesen SH, Marsilio F, et al. (April 2012). "Functional consequence of covalent reaction of phosphoenolpyruvate with UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA)". The Journal of Biological Chemistry. 287 (16): 12657–12667. doi:10.1074/jbc.M112.342725. PMC 3339971. PMID 22378791.
Krekel F, Samland AK, Macheroux P, Amrhein N, Evans JN (October 2000). "Determination of the pKa value of C115 in MurA (UDP-N-acetylglucosamine enolpyruvyltransferase) from Enterobacter cloacae". Biochemistry. 39 (41): 12671–12677. doi:10.1021/bi001310x. PMID 11027147.
Santoro A, Cappello AR, Madeo M, Martello E, Iacopetta D, Dolce V (December 2011). "Interaction of fosfomycin with the glycerol 3-phosphate transporter of Escherichia coli". Biochimica et Biophysica Acta (BBA) - General Subjects. 1810 (12): 1323–1329. doi:10.1016/j.bbagen.2011.07.006. PMID 21791237.
Darabniya A (24 September 2025). "Anti-inflammatory and immunomodulatory properties of fosfomycin: an overlooked potential in a well-known antibiotic". Inflammopharmacology. doi:10.1007/s10787-025-01968-8. ISSN 1568-5608.
Silver LL (2011). "Rational Approaches to Antibacterial Discovery: Pre-Genomic Directed and Phenotypic Screening". In Dougherty T, Pucci MJ (eds.). Antibiotic Discovery and Development. Springer. p. 46. doi:10.1007/978-1-4614-1400-1_2. ISBN 978-1-4614-1400-1.
Hidaka T, Goda M, Kuzuyama T, Takei N, Hidaka M, Seto H (November 1995). "Cloning and nucleotide sequence of fosfomycin biosynthetic genes of Streptomyces wedmorensis". Molecular & General Genetics. 249 (3): 274–80. doi:10.1007/bf00290527. PMID 7500951.
Liu P, Mehn MP, Yan F, Zhao Z, Que L, Liu HW (August 2004). "Oxygenase activity in the self-hydroxylation of (s)-2-hydroxypropylphosphonic acid epoxidase involved in fosfomycin biosynthesis". Journal of the American Chemical Society. 126 (33): 10306–12. Bibcode:2004JAChS.12610306L. doi:10.1021/ja0475050. PMID 15315444.
Higgins LJ, Yan F, Liu P, Liu HW, Drennan CL (October 2005). "Structural insight into antibiotic fosfomycin biosynthesis by a mononuclear iron enzyme". Nature. 437 (7060): 838–44. Bibcode:2005Natur.437..838H. doi:10.1038/nature03924. PMID 16015285.
Woodyer RD, Shao Z, Thomas PM, Kelleher NL, Blodgett JA, Metcalf WW, et al. (November 2006). "Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster". Chemistry & Biology. 13 (11): 1171–1182. doi:10.1016/j.chembiol.2006.09.007. PMID 17113999.
Marocco CP, Davis EV, Finnell JE, Nguyen PH, Mateer SC, Ghiviriga I, et al. (2011). "Asymmetric synthesis of (−)-fosfomycin and its trans-(1S,2S)-diastereomer using a biocatalytic reduction as the key step". Tetrahedron: Asymmetry. 22 (18–19). Elsevier BV: 1784–1789. doi:10.1016/j.tetasy.2011.10.009. ISSN 0957-4166.

drugs.com (Global: 399^th place; English: 333^rd place)

"Fosfomycin Tromethamine Monograph for Professionals". Drugs.com. Archived from the original on 29 October 2019. Retrieved 29 October 2019.
"Fosfomycin (Monurol) Use During Pregnancy". Drugs.com. Archived from the original on 29 October 2019. Retrieved 29 October 2019.
"MONURIL SACHETS 3G". Archived from the original on 28 May 2014. Retrieved 26 May 2014.

ercros.es (Global: low place; English: low place)

"About us: Our history". Encros. Archived from the original on 14 September 2011.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06.
Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. 2019. hdl:10665/312266. ISBN 978-92-4-151552-8.
Meschiari M, Faltoni M, Kaleci S, Tassoni G, Orlando G, Franceschini E, et al. (May 2024). "Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience". International Journal of Antimicrobial Agents. 63 (5) 107134. doi:10.1016/j.ijantimicag.2024.107134. hdl:11380/1334689. PMID 38453094.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Kahan FM, Kahan JS, Cassidy PJ, Kropp H (May 1974). "The mechanism of action of fosfomycin (phosphonomycin)". Annals of the New York Academy of Sciences. 235 (1): 364–386. Bibcode:1974NYASA.235..364K. doi:10.1111/j.1749-6632.1974.tb43277.x. PMID 4605290. S2CID 33013586.
Liu P, Mehn MP, Yan F, Zhao Z, Que L, Liu HW (August 2004). "Oxygenase activity in the self-hydroxylation of (s)-2-hydroxypropylphosphonic acid epoxidase involved in fosfomycin biosynthesis". Journal of the American Chemical Society. 126 (33): 10306–12. Bibcode:2004JAChS.12610306L. doi:10.1021/ja0475050. PMID 15315444.
Higgins LJ, Yan F, Liu P, Liu HW, Drennan CL (October 2005). "Structural insight into antibiotic fosfomycin biosynthesis by a mononuclear iron enzyme". Nature. 437 (7060): 838–44. Bibcode:2005Natur.437..838H. doi:10.1038/nature03924. PMID 16015285.

hres.ca (Global: low place; English: low place)

hpr-rps.hres.ca

"Regulatory Decision Summary - Ivozfo". Health Canada. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

"Monuril 3g granules for oral solution - Summary of Product Characteristics (SmPC)". (emc). 1 June 2021. Archived from the original on 8 March 2022. Retrieved 7 June 2022.
"Fomicyt 40 mg/mL powder for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 11 February 2021. Archived from the original on 7 June 2022. Retrieved 7 June 2022.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Patel SS, Balfour JA, Bryson HM (April 1997). "Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections". Drugs. 53 (4): 637–656. doi:10.2165/00003495-199753040-00007. PMID 9098664. S2CID 46972404.
Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI (April 2008). "Fosfomycin: use beyond urinary tract and gastrointestinal infections". Clinical Infectious Diseases. 46 (7): 1069–1077. doi:10.1086/527442. PMID 18444827.
Falagas ME, Grammatikos AP, Michalopoulos A (October 2008). "Potential of old-generation antibiotics to address current need for new antibiotics". Expert Review of Anti-Infective Therapy. 6 (5): 593–600. doi:10.1586/14787210.6.5.593. PMID 18847400. S2CID 13158593.
Zhanel GG, Zhanel MA, Karlowsky JA (28 March 2020). "Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections". The Canadian Journal of Infectious Diseases & Medical Microbiology. 2020 8513405. Hindawi Limited. doi:10.1155/2020/8513405. PMC 7142339. PMID 32300381.
Meschiari M, Faltoni M, Kaleci S, Tassoni G, Orlando G, Franceschini E, et al. (May 2024). "Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience". International Journal of Antimicrobial Agents. 63 (5) 107134. doi:10.1016/j.ijantimicag.2024.107134. hdl:11380/1334689. PMID 38453094.
Zerbato V, Sanson G, Fusaro L, Gerussi V, Sincovich S, Dellai F, et al. (14 April 2025). "Intravenous Fosfomycin for Difficult-to-Treat Infections: A Real-Life Multicentric Study in Italy". Antibiotics. 14 (4): 401. doi:10.3390/antibiotics14040401. ISSN 2079-6382. PMC 12024000. PMID 40298561.
Antonello RM, Principe L, Maraolo AE, Viaggi V, Pol R, Fabbiani M, et al. (August 2020). "Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies". Antibiotics. 9 (8): 500. doi:10.3390/antibiotics9080500. PMC 7460049. PMID 32785114.
Antonello RM, Di Bella S, Maraolo AE, Luzzati R (June 2021). "Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies". European Journal of Clinical Microbiology & Infectious Diseases. 40 (6): 1117–1126. doi:10.1007/s10096-021-04181-x. PMC 8139892. PMID 33604721.
Di Bella S, Mearelli F, Gatti M (February 2025). "The importance of antibiofilm antibiotics in hardware-associated infections". Clinical Infectious Diseases ciaf064. doi:10.1093/cid/ciaf064. PMID 39935305.
Navas J, León J, Arroyo M, García Lobo JM (October 1990). "Nucleotide sequence and intracellular location of the product of the fosfomycin resistance gene from transposon Tn2921". Antimicrobial Agents and Chemotherapy. 34 (10): 2016–2018. doi:10.1128/AAC.34.10.2016. PMC 171982. PMID 1963292.
Kahan FM, Kahan JS, Cassidy PJ, Kropp H (May 1974). "The mechanism of action of fosfomycin (phosphonomycin)". Annals of the New York Academy of Sciences. 235 (1): 364–386. Bibcode:1974NYASA.235..364K. doi:10.1111/j.1749-6632.1974.tb43277.x. PMID 4605290. S2CID 33013586.
Castañeda-García A, Blázquez J, Rodríguez-Rojas A (April 2013). "Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance". Antibiotics. 2 (2): 217–236. doi:10.3390/antibiotics2020217. PMC 4790336. PMID 27029300.
Omori K, Kitagawa H, Takada M, Maeda R, Nomura T, Kubo Y, et al. (April 2024). "Fosfomycin as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia: A case series and review of the literature". J Infect Chemother. 30 (4): 352–356. doi:10.1016/j.jiac.2023.10.024. PMID 37922987.
Lagatolla C, Mehat JW, La Ragione RM, Luzzati R, Di Bella S (September 2022). "In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium". Antibiotics. 11 (10): 1334. doi:10.3390/antibiotics11101334. PMC 9598191. PMID 36289992.
Rigsby RE, Fillgrove KL, Beihoffer LA, Armstrong RN (2005). "Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily". Gluthione [sic] Transferases and Gamma-Glutamyl Transpeptidases. Methods in Enzymology. Vol. 401. pp. 367–379. doi:10.1016/S0076-6879(05)01023-2. ISBN 978-0-12-182806-6. PMID 16399398.
Sharma SV, Jothivasan VK, Newton GL, Upton H, Wakabayashi JI, Kane MG, et al. (July 2011). "Chemical and Chemoenzymatic syntheses of bacillithiol: a unique low-molecular-weight thiol amongst low G + C Gram-positive bacteria". Angewandte Chemie. 50 (31): 7101–7104. doi:10.1002/anie.201100196. PMID 21751306.
Roberts AA, Sharma SV, Strankman AW, Duran SR, Rawat M, Hamilton CJ (April 2013). "Mechanistic studies of FosB: a divalent-metal-dependent bacillithiol-S-transferase that mediates fosfomycin resistance in Staphylococcus aureus". The Biochemical Journal. 451 (1): 69–79. doi:10.1042/BJ20121541. PMC 3960972. PMID 23256780.
García P, Arca P, Evaristo Suárez J (July 1995). "Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate". Antimicrobial Agents and Chemotherapy. 39 (7): 1569–1573. doi:10.1128/aac.39.7.1569. PMC 162783. PMID 7492106.
Brown ED, Vivas EI, Walsh CT, Kolter R (July 1995). "MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli". Journal of Bacteriology. 177 (14): 4194–4197. doi:10.1128/jb.177.14.4194-4197.1995. PMC 177162. PMID 7608103.
Zhu JY, Yang Y, Han H, Betzi S, Olesen SH, Marsilio F, et al. (April 2012). "Functional consequence of covalent reaction of phosphoenolpyruvate with UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA)". The Journal of Biological Chemistry. 287 (16): 12657–12667. doi:10.1074/jbc.M112.342725. PMC 3339971. PMID 22378791.
Krekel F, Samland AK, Macheroux P, Amrhein N, Evans JN (October 2000). "Determination of the pKa value of C115 in MurA (UDP-N-acetylglucosamine enolpyruvyltransferase) from Enterobacter cloacae". Biochemistry. 39 (41): 12671–12677. doi:10.1021/bi001310x. PMID 11027147.
Santoro A, Cappello AR, Madeo M, Martello E, Iacopetta D, Dolce V (December 2011). "Interaction of fosfomycin with the glycerol 3-phosphate transporter of Escherichia coli". Biochimica et Biophysica Acta (BBA) - General Subjects. 1810 (12): 1323–1329. doi:10.1016/j.bbagen.2011.07.006. PMID 21791237.
Hidaka T, Goda M, Kuzuyama T, Takei N, Hidaka M, Seto H (November 1995). "Cloning and nucleotide sequence of fosfomycin biosynthetic genes of Streptomyces wedmorensis". Molecular & General Genetics. 249 (3): 274–80. doi:10.1007/bf00290527. PMID 7500951.
Liu P, Mehn MP, Yan F, Zhao Z, Que L, Liu HW (August 2004). "Oxygenase activity in the self-hydroxylation of (s)-2-hydroxypropylphosphonic acid epoxidase involved in fosfomycin biosynthesis". Journal of the American Chemical Society. 126 (33): 10306–12. Bibcode:2004JAChS.12610306L. doi:10.1021/ja0475050. PMID 15315444.
Higgins LJ, Yan F, Liu P, Liu HW, Drennan CL (October 2005). "Structural insight into antibiotic fosfomycin biosynthesis by a mononuclear iron enzyme". Nature. 437 (7060): 838–44. Bibcode:2005Natur.437..838H. doi:10.1038/nature03924. PMID 16015285.
Woodyer RD, Shao Z, Thomas PM, Kelleher NL, Blodgett JA, Metcalf WW, et al. (November 2006). "Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster". Chemistry & Biology. 13 (11): 1171–1182. doi:10.1016/j.chembiol.2006.09.007. PMID 17113999.

ncbi.nlm.nih.gov

Zhanel GG, Zhanel MA, Karlowsky JA (28 March 2020). "Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections". The Canadian Journal of Infectious Diseases & Medical Microbiology. 2020 8513405. Hindawi Limited. doi:10.1155/2020/8513405. PMC 7142339. PMID 32300381.
Zerbato V, Sanson G, Fusaro L, Gerussi V, Sincovich S, Dellai F, et al. (14 April 2025). "Intravenous Fosfomycin for Difficult-to-Treat Infections: A Real-Life Multicentric Study in Italy". Antibiotics. 14 (4): 401. doi:10.3390/antibiotics14040401. ISSN 2079-6382. PMC 12024000. PMID 40298561.
Antonello RM, Principe L, Maraolo AE, Viaggi V, Pol R, Fabbiani M, et al. (August 2020). "Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies". Antibiotics. 9 (8): 500. doi:10.3390/antibiotics9080500. PMC 7460049. PMID 32785114.
Antonello RM, Di Bella S, Maraolo AE, Luzzati R (June 2021). "Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies". European Journal of Clinical Microbiology & Infectious Diseases. 40 (6): 1117–1126. doi:10.1007/s10096-021-04181-x. PMC 8139892. PMID 33604721.
Navas J, León J, Arroyo M, García Lobo JM (October 1990). "Nucleotide sequence and intracellular location of the product of the fosfomycin resistance gene from transposon Tn2921". Antimicrobial Agents and Chemotherapy. 34 (10): 2016–2018. doi:10.1128/AAC.34.10.2016. PMC 171982. PMID 1963292.
Castañeda-García A, Blázquez J, Rodríguez-Rojas A (April 2013). "Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance". Antibiotics. 2 (2): 217–236. doi:10.3390/antibiotics2020217. PMC 4790336. PMID 27029300.
Lagatolla C, Mehat JW, La Ragione RM, Luzzati R, Di Bella S (September 2022). "In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium". Antibiotics. 11 (10): 1334. doi:10.3390/antibiotics11101334. PMC 9598191. PMID 36289992.
Roberts AA, Sharma SV, Strankman AW, Duran SR, Rawat M, Hamilton CJ (April 2013). "Mechanistic studies of FosB: a divalent-metal-dependent bacillithiol-S-transferase that mediates fosfomycin resistance in Staphylococcus aureus". The Biochemical Journal. 451 (1): 69–79. doi:10.1042/BJ20121541. PMC 3960972. PMID 23256780.
García P, Arca P, Evaristo Suárez J (July 1995). "Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate". Antimicrobial Agents and Chemotherapy. 39 (7): 1569–1573. doi:10.1128/aac.39.7.1569. PMC 162783. PMID 7492106.
Brown ED, Vivas EI, Walsh CT, Kolter R (July 1995). "MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli". Journal of Bacteriology. 177 (14): 4194–4197. doi:10.1128/jb.177.14.4194-4197.1995. PMC 177162. PMID 7608103.
Zhu JY, Yang Y, Han H, Betzi S, Olesen SH, Marsilio F, et al. (April 2012). "Functional consequence of covalent reaction of phosphoenolpyruvate with UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA)". The Journal of Biological Chemistry. 287 (16): 12657–12667. doi:10.1074/jbc.M112.342725. PMC 3339971. PMID 22378791.

dailymed.nlm.nih.gov

"Monurol- fosfomycin tromethamine powder". DailyMed. 24 October 2019. Archived from the original on 7 June 2022. Retrieved 7 June 2022.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Patel SS, Balfour JA, Bryson HM (April 1997). "Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections". Drugs. 53 (4): 637–656. doi:10.2165/00003495-199753040-00007. PMID 9098664. S2CID 46972404.
Falagas ME, Grammatikos AP, Michalopoulos A (October 2008). "Potential of old-generation antibiotics to address current need for new antibiotics". Expert Review of Anti-Infective Therapy. 6 (5): 593–600. doi:10.1586/14787210.6.5.593. PMID 18847400. S2CID 13158593.
Kahan FM, Kahan JS, Cassidy PJ, Kropp H (May 1974). "The mechanism of action of fosfomycin (phosphonomycin)". Annals of the New York Academy of Sciences. 235 (1): 364–386. Bibcode:1974NYASA.235..364K. doi:10.1111/j.1749-6632.1974.tb43277.x. PMID 4605290. S2CID 33013586.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
https://www.tga.gov.au/resources/prescription-medicines-registrations/cipfosin-cipla-fosfomycin-cipla-australia-pty-ltd

web.archive.org (Global: 1^st place; English: 1^st place)

"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
"Regulatory Decision Summary - Ivozfo". Health Canada. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
"Monuril 3g granules for oral solution - Summary of Product Characteristics (SmPC)". (emc). 1 June 2021. Archived from the original on 8 March 2022. Retrieved 7 June 2022.
"Fomicyt 40 mg/mL powder for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 11 February 2021. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
"Monurol- fosfomycin tromethamine powder". DailyMed. 24 October 2019. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
"Fosfomycin Tromethamine Monograph for Professionals". Drugs.com. Archived from the original on 29 October 2019. Retrieved 29 October 2019.
"Fosfomycin (Monurol) Use During Pregnancy". Drugs.com. Archived from the original on 29 October 2019. Retrieved 29 October 2019.
"MONURIL SACHETS 3G". Archived from the original on 28 May 2014. Retrieved 26 May 2014.
"About us: Our history". Encros. Archived from the original on 14 September 2011.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Zerbato V, Sanson G, Fusaro L, Gerussi V, Sincovich S, Dellai F, et al. (14 April 2025). "Intravenous Fosfomycin for Difficult-to-Treat Infections: A Real-Life Multicentric Study in Italy". Antibiotics. 14 (4): 401. doi:10.3390/antibiotics14040401. ISSN 2079-6382. PMC 12024000. PMID 40298561.
Darabniya A (24 September 2025). "Anti-inflammatory and immunomodulatory properties of fosfomycin: an overlooked potential in a well-known antibiotic". Inflammopharmacology. doi:10.1007/s10787-025-01968-8. ISSN 1568-5608.
Marocco CP, Davis EV, Finnell JE, Nguyen PH, Mateer SC, Ghiviriga I, et al. (2011). "Asymmetric synthesis of (−)-fosfomycin and its trans-(1S,2S)-diastereomer using a biocatalytic reduction as the key step". Tetrahedron: Asymmetry. 22 (18–19). Elsevier BV: 1784–1789. doi:10.1016/j.tetasy.2011.10.009. ISSN 0957-4166.

Fosfomycin (English Wikipedia)

archive.org (Global: 6th place; English: 6th place)

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)

ercros.es (Global: low place; English: low place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

hres.ca (Global: low place; English: low place)

hpr-rps.hres.ca

medicines.org.uk (Global: 3,823rd place; English: 2,387th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

web.archive.org (Global: 1st place; English: 1st place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

archive.org (Global: 6^th place; English: 6^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 399^th place; English: 333^rd place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

nih.gov (Global: 4^th place; English: 4^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 5^th place; English: 5^th place)